anti-CD7 CAR T-cell therapy (Guangzhou Bio-gene Technology/Hebei Yanda Lu Daopei Hospital)

N/A

Report date: 2025/03/14 16:48:18

Base Information

Drug Nameanti-CD7 CAR T-cell therapy (Guangzhou Bio-gene Technology/Hebei Yanda Lu Daopei Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionT-cell antigen CD7 modulators
TargetsT-cell antigen CD7
Therapy Area/IndicationsLymphomaPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHebei Yanda Ludaopei Hospital
China Registration ClassN/A

Develop Information

Active CompaniesHebei Yanda Ludaopei HospitalGuangzhou Bio-Gene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphomaPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A